Latest Information Update: 31 Jan 2008
At a glance
- Originator Nissan Chemical Industries
- Class Antiasthmatics
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 24 Apr 2007 No development reported - Phase-I for Asthma in United Kingdom (unspecified route)
- 03 Feb 2000 Phase-I clinical trials for Asthma in United Kingdom (Unknown route)
- 14 Sep 1999 New profile